Akeso's HARMONi-2 study showed its drug, ivonescimab, significantly reduced the risk of death by 27% compared to pembrolizumab in PD-L1-positive advanced NSCLC, with an 8.2-month improvement in median overall survival. This positive clinical trial data represents a substantial competitive development in the oncology space, potentially shifting market share and treatment paradigms.
Akeso reported compelling results from its HARMONi-2 study, demonstrating that ivonescimab monotherapy reduced the risk of death by 27% compared to Merck's pembrolizumab (Keytruda) in PD-L1-positive advanced NSCLC patients. This is a significant clinical win, as it directly challenges the current standard of care. The improved median overall survival of 8.2 months and a hazard ratio of 0.58 in the PD-L1 high expression subgroup highlight ivonescimab's potential efficacy. This news is a strong positive for Akeso and its partner Summit Therapeutics, which is conducting the global Phase III HARMONi-7 study. For Merck, it represents a competitive threat to its blockbuster drug, Keytruda. Short-term, Akeso and Summit could see increased investor confidence and stock appreciation. Long-term, successful Phase III trials and subsequent market approval could lead to substantial market share gains for ivonescimab, posing a significant risk to Merck's oncology revenue stream.